What progesterone regimen is recommended for the treatment of menorrhagia?

Progesterone Regimen for Menorrhagia

For acute menorrhagia control, use oral medroxyprogesterone acetate (MPA) 20 mg daily for 10-14 days, or for severe bleeding requiring rapid control, give 60-120 mg on day 1 followed by 20 mg daily for 10 days. For ongoing heavy menstrual bleeding management, use cyclic oral progestins for 21 days per cycle (days 5-26) rather than luteal phase dosing (days 14-27), as the longer regimen is more effective 1, 2.

Acute Bleeding Management

When facing acute menorrhagia requiring immediate control:

• High-dose MPA protocol: Administer 60-120 mg total dose on the first day, then 20 mg daily for 10 subsequent days 3

  • This achieves bleeding cessation in 25% of patients within 24 hours
  • 75% stop bleeding within 4 days
  • Particularly effective when hemoglobin is not severely depleted

• Standard acute regimen: MPA 20 mg daily for 10-14 days can be used for less severe acute bleeding 2

Chronic Heavy Menstrual Bleeding

For ongoing menorrhagia management, the evidence strongly favors extended progestin regimens:

Preferred regimen: Oral progestin for 21 days per cycle (cycle days 5-26) 1, 2

• Significantly more effective than luteal phase dosing (days 14-27)
• Options include:
  • Medroxyprogesterone acetate: 5-10 mg daily 4
  • Micronized progesterone: 200 mg daily 4, 5
  • Norethindrone acetate: 5 mg daily 4

Important caveat: Luteal phase progestin therapy (days 14-27) is ineffective for ovulatory menorrhagia and offers no advantage over other medical therapies 1. This is a common prescribing error to avoid.

Specific Clinical Scenarios

For Menorrhagia with Intact Ovulation

• Micronized progesterone 200 mg at bedtime, cycle days 4-28, combined with ibuprofen 200 mg every 6 hours during menses 5
• This addresses both the hormonal imbalance and prostaglandin-mediated bleeding

For Perimenopausal Women

• Micronized progesterone 300 mg at bedtime, given cyclically (days 14-27 or 14 days on/14 days off) 5
• Can transition to daily dosing in late perimenopause if cyclic bleeding becomes problematic

For Women with Bleeding Disorders

• Combine progestin therapy with tranexamic acid and iron supplementation 6
• This pragmatic approach reduces transfusion requirements and improves quality of life
• Reserve clotting factor concentrates for refractory cases only

For Women at VTE Risk

• Avoid high-dose progestins and estrogen-containing therapies 7
• Use lower-dose progestin-only formulations
• Consider tranexamic acid as primary therapy (non-hormonal alternative)

Alternative Delivery Routes

When oral therapy is contraindicated or poorly tolerated:

• Vaginal micronized progesterone: 200 mg daily for 12-14 days per month 4

  • Achieves adequate endometrial protection with fewer systemic side effects
  • Particularly useful when oral progestins cause intolerable mood or physical symptoms

• Levonorgestrel-releasing IUS: Most effective long-term option, though not strictly "progesterone therapy" 1, 2

  • Superior to all oral progestin regimens for menstrual blood loss reduction
  • Consider when oral therapy fails or is unacceptable

Key Clinical Pitfalls

1. Don't use luteal phase dosing (days 14-27) for menorrhagia - this regimen is ineffective for ovulatory heavy bleeding despite being commonly prescribed 1

2. Endometrial assessment is mandatory in women ≥35 years with recurrent anovulation, younger women with endometrial cancer risk factors, or those with bleeding unresponsive to medical therapy 2

3. Micronized progesterone is preferred over synthetic progestins when cardiovascular risk is a concern, as it has lower thrombotic risk and better metabolic profile 8

4. Duration matters: The 21-day regimen (days 5-26) provides significantly better bleeding control than shorter luteal phase regimens, though women may find it less acceptable due to prolonged hormone exposure 1

Monitoring and Adjustment

• Assess response after 2-3 cycles
• If bleeding persists despite 21-day progestin therapy, consider structural causes (polyps, fibroids) requiring imaging
• Switch progestin type if side effects (mood changes, bloating, breast tenderness) are intolerable 4
• Hemoglobin monitoring is essential, particularly in acute bleeding scenarios 3

The evidence clearly demonstrates that extended-cycle progestin regimens are superior to luteal phase dosing for menorrhagia control, and micronized progesterone offers the best safety profile when cardiovascular or thrombotic risk is present.